Skip to main content

Table 3 CD4+ count and high-sensitivity CRP pre-cART and longitudinally over 12 weeks, categorized by neuropathic symptom status

From: Plasma cytokine profiles in HIV-1 infected patients developing neuropathic symptoms shortly after commencing antiretroviral therapy: a case-control study

Variable Time point Time effect Group effect
Median (IQR), pg/ml Neuropathic symptom group Median (IQR) Control group Median (IQR)
CD4+ count, cells/mm3 Baseline 141 (110; 189) 145 (109; 181) 138 (110; 194)
  Week 24 272 (204; 368) 298 (210; 457) 260 (179; 351)
hs-CRP, mg/L Baseline 2.70 (0.90; 6.70) 2.90 (0.90; 6.70) 2.60 (0.90; 5.40)
  Week 2 6.70 (2.10; 18.50) 8.40 (3.40; 17.00) 5.30 (1.80; 19.30)
  Week 4 6.50 (3.30; 26.50) 8.40 (3.50; 30.60) 4.20 (3.30; 15.00)
  Week 12 3.95 (1.50; 7.20) 3.80 (1.50; 8.30) 4.20 (1.00; 6.70)
  1. Incident neuropathic symptoms developed within 12 weeks of starting cART.
  2. The control group refers to the symptom-free nested control group paired for previously identified risk factors.
  3. Time effect: Bold numbers denote values different from baseline, p < 0.05.
  4. Group effect: Bold numbers denote values different between groups compared to baseline, p < 0.05.
  5. Abbreviations: IQR interquartile range, hs-CRP high-sensitivity C-reactive protein.